Thursday, May 11th, 2023
This randomized, double-blind, crossover trial examined the effects of an extended-release formulation of nalbuphine in 32 adult patients with IPF-related chronic cough. The primary endpoint was the percent change from baseline in hourly daytime cough frequency, which was objectively measured using the Vitalograph VitaloJAK digital cough monitor.
Vitalograph is a global leader in respiratory diagnostics. We produce high quality, accurate and reliable, respiratory medical devices & services for primary, secondary healthcare and occupational health. We deliver successful clinical trials for leading pharmaceutical companies, biotechs and research organisations.
© Vitalograph 2023 | Privacy Policy | Cookies
Products may not be available in your region. Contact us for more details. Always read the product IFU before use.
